Abstract

A number of plants used in folk medicine in Thailand and Eastern Asia are attracting interest due to the high bioactivities of their extracts. The aim of this study was to screen the edible leaf extracts of 20 plants found in Thailand and investigate the potential neuroprotective effects of the most bioactive sample. The total phenol and flavonoid content and 2,2-diphenyl-1-picrylhydrazyl radical-scavenging activity were determined for all 20 leaf extracts. Based on these assays, Glochidion littorale leaf extract (GLE), which showed a high value in all tested parameters, was used in further experiments to evaluate its effects on neurodegeneration in Caenorhabditis elegans. GLE treatment ameliorated H2O2-induced oxidative stress by attenuating the accumulation of reactive oxygen species and protected the worms against 1-methyl-4-phenylpyridinium-induced neurodegeneration. The neuroprotective effects observed may be associated with the activation of the transcription factor DAF-16. The characterization of this extract by LC-MS identified several phenolic compounds, including myricetin, coumestrin, chlorogenic acid, and hesperidin, which may play a key role in neuroprotection. This study reports the novel neuroprotective activity of GLE, which may be used to develop treatments for neurodegenerative diseases such as Parkinson’s syndrome.

Highlights

  • Neurodegenerative disorders including Alzheimer’s disease and Parkinson’s disease (PD) pose major health and financial concerns to global health care organizations [1]

  • The extracts of 20 edible plant leaves from Thailand were screened, and G. littorale was selected for further investigation because it showed high phenol content, flavonoid content, and radical-scavenging activity

  • Our data showed that Glochidion littorale leaf extract (GLE) protected C. elegans against H2O2-induced oxidative stress by reducing intracellular reactive oxygen species (ROS) accumulation

Read more

Summary

Introduction

Neurodegenerative disorders including Alzheimer’s disease and Parkinson’s disease (PD) pose major health and financial concerns to global health care organizations [1]. The human lifespan has increased in the last few decades in industrialized countries, the prevalence of age-related diseases has increased. The incidence of late-onset disorders such as neurological disruptions is expected to increase rapidly over the few decades. It is crucial to encourage studies and perform clinical trials on compounds that may have the potential to cure, prevent, or at least delay the onset of neurodegenerative diseases [2]. In PD pathogenesis, increased production of reactive oxygen species (ROS) plays a key role in the loss of DA cells [4]. The 1-methyl-4-phenylpyridinium (MPP+), which inhibits mitochondrial complex I activity, can induce PD-like symptoms in humans and animal models [6]

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call